Format

Send to

Choose Destination
J Psychopharmacol. 2016 Dec;30(12):1220-1229. Epub 2016 Nov 17.

Psychedelics in the treatment of unipolar mood disorders: a systematic review.

Author information

1
The Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK james.rucker@kcl.ac.uk.
2
South West London and St George's Mental Health NHS Trust, London, UK.
3
The Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, UK.
4
South London and Maudsley NHS Foundation Trust, London, UK.
5
King's College London School of Medicine, London, UK.

Abstract

Unipolar mood disorders, including major depressive disorder and persistent depressive disorder (dysthymia), confer high rates of disability and mortality and a very high socioeconomic burden. Current treatment is suboptimal in most cases and there is little of note in the pharmaceutical development pipeline. The psychedelic drugs, including lysergic acid diethylamide and psilocybin, were used extensively in the treatment of mood disorders, and other psychiatric conditions, before their prohibition in the late 1960s. They are relatively safe when used in medically controlled environments, with no reported risk of dependence. Here, we present a systematic review of published clinical treatment studies using psychedelics in patients with broadly defined UMD, and consider their place in psychiatry. Whilst all of the included studies have methodological shortcomings, of 423 individuals in 19 studies, 335 (79.2%) showed clinician-judged improvement after treatment with psychedelics. A recently completed pilot study in the UK favours the use of psilocybin with psychological support in treatment resistant depressive disorder. The evidence overall strongly suggests that psychedelics should be re-examined in modern clinical trials for their use in unipolar mood disorders and other non-psychotic mental health conditions.

KEYWORDS:

Depression; LSD; dysthymia; psilocybin; psychedelics

PMID:
27856684
DOI:
10.1177/0269881116679368
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center